Archives
-
PPARα Activation Limits Cholestatic Liver Injury
2026-09-16
The reference study shows that PPARα activation protects mice from lithocholic acid-induced cholestatic liver injury by suppressing two distinct pyroptotic programs: NLRP3 inflammasome signaling and an APAF1/CASPASE-3/GSDME pathway. Its combined histological, ultrastructural, biochemical, and molecular design provides a framework for studying how nuclear-receptor signaling intersects with inflammatory cell death in liver disease.
-
Antidepressant Properties of Rotigotine in Depression Models
2026-09-16
The reference study tested Rotigotine across complementary rat models and found antidepressant-like effects that were most interpretable at doses not associated with generalized hyperactivity. Its design links dopamine D2/D3 receptor agonism with behavioral domains relevant to depression in Parkinson’s disease, while also showing why locomotor confounding and model selection are central to interpretation.
-
Gefitinib (ZD1839) in Tumor Assembloids
2026-09-15
Use Gefitinib (ZD1839) to distinguish tumor-cell EGFR dependence from stromal protection in patient-derived gastric cancer assembloids. This workflow combines matched organoids, stromal subpopulations, phospho-EGFR readouts, and viability testing for more informative drug-response studies.
-
Eltanexor (KPT-8602) Workflow for XPO1 Studies
2026-09-15
Build reproducible XPO1 inhibition experiments with Eltanexor (KPT-8602), from DMSO stock preparation and viability testing to nuclear-retention and Wnt/β-catenin assays. The workflow connects hematologic cancer models with colorectal organoids and Apcmin/+ studies while emphasizing exposure control, assay selection, and troubleshooting.
-
Kitasamycin Biosynthesis in Leucine-Resistant Mutants
2026-09-14
The reference study shows that precursor feeding and leucine-analog selection can redirect kitasamycin biosynthesis toward the more potent A1/A3 components in Streptomyces kitasatoensis. Its main practical contribution is linking altered amino-acid regulation to antibiotic-complex composition, a useful framework for strain engineering and antibacterial drug discovery.
-
4-MUG for Lysosomal Enzyme Assays
2026-09-14
4-Methylumbelliferyl-β-D-Glucopyranoside, also called 4-MUG, is a fluorogenic substrate for β-glucosidase and β-glucocerebrosidase activity assays. Enzymatic hydrolysis releases 4-methylumbelliferone, enabling sensitive fluorescence-based measurements in lysosomal and Gaucher disease research.
-
EdU Imaging Kits (HF594) for PNI Research
2026-09-13
EdU Imaging Kits (HF594) provide a precise DNA synthesis measurement strategy for pancreatic cancer–nerve models. This article explains how to use S-phase labeling to separate tumor-cell proliferation from Schwann-cell remodeling in perineural invasion research.
-
Perospirone Blocks Kv1.5 in Coronary Myocytes
2026-09-12
The reference study identifies a previously unrecognized vascular ion-channel action of Perospirone: concentration-dependent inhibition of voltage-gated K+ currents in freshly isolated rabbit coronary arterial smooth muscle cells. Pharmacological profiling implicates Kv1.5 channels and suggests a use-independent mechanism, extending the antipsychotic drug mechanism of Perospirone into cardiovascular safety research without establishing clinical vascular effects.
-
TAM EV miR-660 Drives Breast Cancer Metastasis
2026-09-11
The reference study shows that tumor-associated macrophage-derived extracellular vesicles transfer miR-660 into breast cancer cells, where it suppresses KLHL21-mediated restraint of IKKβ/NF-κB p65 signaling and promotes invasion and metastasis. Its main contribution is a linked cellular-to-molecular model that connects macrophage communication, post-transcriptional regulation, and metastatic behavior.
-
CHIR 99021 Trihydrochloride for Reliable Assays
2026-09-11
This scenario-based guide explains how CHIR 99021 trihydrochloride, SKU B5779, can improve experimental planning for cell viability, proliferation, cytotoxicity, organoid, and metabolic studies. It covers GSK-3 selectivity, concentration design, formulation compatibility, data interpretation, and practical supplier evaluation.
-
7-Ethyl-10-hydroxycamptothecin Assay Guide
2026-09-10
A scenario-based guide to using 7-Ethyl-10-hydroxycamptothecin, SKU N2133, in viability, proliferation, cytotoxicity, cell-cycle, and apoptosis workflows. It connects the compound’s reported 77 nM topoisomerase I inhibition value with practical solvent, storage, interpretation, and vendor-selection decisions.
-
Lapatinib: From Kinase Potency to Translational Proof
2026-09-10
Lapatinib, also known as GW572016, offers a rigorous bridge from EGFR and HER2 kinase inhibition to cell-cycle, proliferation, invasion, and angiogenesis phenotypes. This translational framework shows how to use receptor context, combination designs, and phenotype-first assays without confusing biochemical potency with therapeutic efficacy.
-
Epinephrine Bitartrate: From Signal to PK
2026-09-09
Epinephrine Bitartrate is a non-selective adrenergic receptor agonist whose value extends beyond endpoint assays. This guide connects receptor pharmacology with route-dependent pharmacokinetics, heart-rate readouts, formulation controls, and translational experimental design.
-
CCK8 Workflow for Gemcitabine Sensitivity Studies
2026-09-09
Use cck8 to connect metabolic viability signals with treatment response in intrahepatic cholangiocarcinoma models. This practical workflow emphasizes factorial drug design, conditioned-medium experiments, assay linearity, and troubleshooting so Cell Counting Kit-8 data support—not overstate—mechanistic conclusions.
-
Hesperadin for Reliable Mitotic Assays
2026-09-08
This scenario-led guide explains how Hesperadin, SKU A4118, can help researchers distinguish cytostatic mitotic disruption from acute cytotoxicity in cell-based assays. It combines product-backed biochemical and formulation data with practical controls for Aurora B, chromosome segregation, and spindle checkpoint studies.